Guide: Eight tips for ensuring a successful ELISA
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
List view / Grid view
Biomarkers are a naturally occurring molecule, gene, or characteristic by which a particular disease can be identified.
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
Sino Biological is an international reagent supplier and service provider. The company specialises in recombinant protein production and antibody development.
Solutions to help you understand viral diseases and translate your research findings into better treatments and vaccines.
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
Despite many companies considering digital transformation a top priority, research shows that 70% of digital transformation initiatives fail. In this ebook, we explore why and how the right approach can see your organisation succeed.
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
25 May 2021 | By Metabolon
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
Solutions to aid understanding of cellular and molecular pathways in diabetes and translate these findings into prevention and treatment strategies.
The development of a Parkinson’s disease model, using hiPSC-derived neural cells, to assess alpha-synuclein pre-formed fibril-induced toxicity.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.